초록 ▼

The present invention provides for a method for treating human or animal patients with paclitaxel formulation, the method comprising an intratumoral dose of a paclitaxel formulation and an intravenous dose of paclitaxel. The intravenous dose occurs about 1 to about 7 days after the intratumoral dose

The present invention provides for a method for treating human or animal patients with paclitaxel formulation, the method comprising an intratumoral dose of a paclitaxel formulation and an intravenous dose of paclitaxel. The intravenous dose occurs about 1 to about 7 days after the intratumoral dose. The paclitaxel formulation may typically be either a paclitaxel/HSA formulation or paclitaxel/γ-globulin formulation.

대표청구항 ▼

1. A method of administering paclitaxel to a patient having a tumor, the method comprising; introducing an intratumoral dose of a paclitaxel formulation; and, subsequently providing an initial intravenous infusion of paclitaxel about 24 hours to about 7 days after the intratumoral dose. 2. The

1. A method of administering paclitaxel to a patient having a tumor, the method comprising; introducing an intratumoral dose of a paclitaxel formulation; and, subsequently providing an initial intravenous infusion of paclitaxel about 24 hours to about 7 days after the intratumoral dose. 2. The method of claim 1, wherein the paclitaxel formulation is a mixture of paclitaxel and plasma protein in an amount effective to solubilize the paclitaxel. 3. A method of treating a patient having a tumor comprising: administering to a tumor at least one intratumoral dose of a first formulation comprising paclitaxel and a plasma protein, thereby inducing apoptosis; and administering intravenously to a patient at least one dose of a second formulation comprising paclitaxel, the first dose of the second formulation occurring about 1 to about 7 days after the the intratumoral dose, wherein the first and second formulations are the same or different, and wherein the amount of plasma protein in the first formulation is an amount effective to solubilize the paclitaxel. 4. The method of claim 3, wherein the plasma protein is selected from the group consisting of human serum albumin and γ-globulin. 5. The method of claim 3, wherein the dose of paclitaxel formulation is between about 1 to about 60 mg of paclitaxel. 6. The method of claim 3, wherein the paclitaxel formulation is between about 4 to about 10 mg/ml paclitaxel. 7. The method of claim 3, wherein the intratumoral dose is administered by a plurality of injections of the paclitaxel formulation. 8. The method of claim 3, wherein the intratumoral dose of the paclitaxel formulation is administered by syringe pump. 9. The method of claim 3, wherein the intravenous infusion of paclitaxel comprises administering between about 70 to about 280 mg of paclitaxel. 10. The method of claim 3, wherein the intravenous infusion of paclitaxel comprises administering between about 100 to about 200 mg/m2of paclitaxel. 11. The method of claim 3, wherein the intravenous infusion of paclitaxel comprises administering between about 135 to about 175 mg/m2of paclitaxel. 12. The method of claim 3, wherein the intravenous infusion of paclitaxel comprises administering a mixture of paclitaxel and plasma protein in an amount effective to solubilize the paclitaxel. 13. The method of claim 12, wherein the solubilizing plasma protein is selected from the group consisting of human serum albumin and γ-globulin. 14. The method of claim 1, wherein the intravenous infusion of paclitaxel comprises administering paclitaxel and polyoxyethylated castor oil. 15. The method of claim 3, wherein the intravenous infusion of paclitaxel comprises administering a plurality of intravenous infusions subsequent to the intratumoral dose. 16. The method of claim 3, further comprising administering an additional intravenous infusion of the paclitaxel formulation subsequent to the intravenous infusion. 17. The method of claim 16, wherein the additional intravenous dose is administered about 4 to about 21 days subsequent to the intravenous infusion. 18. The method of claim 16, further comprising administering an intratumoral dose of the paclitaxel formulation subsequent to the additional intravenous infusion. 19. The method of claim 3, further comprising administering an additional intratumoral dose of the paclitaxel formulation subsequent to the intravenous infusion. 20. The method of claim 19, wherein the additional intratumoral dose is administered about 4 to about 21 days subsequent to the intravenous infusion.